Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and ...

Finnish biopharmaceutical company Aplagon has secured a financing of €7m ($7.24m) to advance its heparin proteoglycan mimetic, APAC, to primarily support the initiation of a Phase IIa trial for ...

Study performed at the Department of Dermatology, 12 de Octubre University Hospital, Madrid, Spain.

Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and ...

There are anticoagulants such as warfarin, heparin, and new oral medications like rivaroxaban and apixaban. These have been widely applied in patients with atrial fibrillation, a clinical ...

Pedraza-Cruz, P. , Varghese, M. , DiGiacomo, D. , Spencer, C. and Horani, O. (2025) Adrenal Crisis Secondary to Bilateral ...

PORTLAND, OR, UNITED STATES, January 31, 2025 /EINPresswire / -- The global heparin market is experiencing substantial growth as demand for effective anticoagulant therapies increases worldwide.

An­thos Ther­a­peu­tics’ an­ti­co­ag­u­lant pos­es a low­er risk of bleed­ing events than Bay­er and J&J’s Xarel­to when used to pre­vent blood clots in atri­al fib­ril­la ...

Promising results show that abelacimab could revolutionize anticoagulation therapy by slashing bleeding risks without compromising stroke protection for patients with atrial fibrillation.

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study.